WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of MK-0677 for the manufacture of a medicament for the treatment for growth hormone deficiency (GHD) in children known to have short stature and equivalent growth potential compared to rhGH,

wherein a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 μg/L in response to a single oral dose of MK-0677; and

(ii.) a baseline serum IGF-I of >30ng/mL.

2. The use of Claim 1, wherein the medicament comprises a single, 0.8 mg/kg/d dose of MK-0677 and is to be administered orally.

3. The use of Claim 1, wherein the medicament is in the form of at least one mini-tablet for oral administration.

4. The use of Claim 3, wherein the at least one mini-tablet comprises 2 mg of MK-0677.

5. The use of Claim 1, wherein the GHD is pediatric GHD.

6. The use of Claim 1, wherein the medicament is to be administered orally with assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

7. Use of a therapeutically effective amount of MK-0677 in the manufacture of an oral medicament for GHD in children,

found using a theranostic test to have short stature and equivalent growth potential compared to rhGH;

wherein a child has equivalent growth potential compared to rhGH when the child has:

(i.) a peak serum GH ≥5 μg/L in response to a single oral dose of MK-0677; and

(ii.) a baseline serum IGF-I of >30ng/mL.

8. The use of Claim 7, wherein the oral medicament comprises a single, 0.8 mg/kg/d dose of MK-0677 and is to be administered orally.

9. The use of Claim 7, wherein the oral medicament is in the form of at least one mini-tablet for oral administration.

10. The use of Claim 9, wherein the at least one mini-tablet comprises 2 mg of MK-0677.

11. The use of Claim 7, wherein the oral medicament is to be administered with assistance of a device capable of dispensing at least one MK-0677 mini-tablet.

12. The use of Claim 7, wherein the GHD is pediatric GHD.

13. The use of Claim 7, wherein the children found using the theranostic test to have short stature and equivalent growth potential compared to rhGH, each has:

(i.) a peak serum GH of ≥5 μg/L in response to a single oral dose of MK-0677; and

(ii.) a baseline serum IGF-I of >30ng/mL.

14. The use of Claim 13, wherein the single oral dose of MK-0677 is 0.8 mg/kg/d.

15. The use of Claim 1, wherein the medicament is manufactured for treatment and the said treatment is to be maintained for more than 6 months.

16. The use of Claim 1, wherein the medicament is manufactured for treatment and the said treatment is to be maintained for at least 7 months.

17. The use of Claim 1, wherein the medicament is manufactured for treatment and the said treatment is to be maintained until growth potential is exhausted.

18. The use of Claim 7, wherein the oral medicament is manufactured for treatment and the said treatment is to be maintained for more than 6 months.

19. The use of Claim 7, wherein the oral medicament is manufactured for treatment and the said treatment is to be maintained for at least 7 months.

20. The use of Claim 7, wherein the oral medicament is manufactured for treatment and the said treatment is to be maintained until growth potential is exhausted.